본문 바로가기
KERD
논문KCI 등재

Opsonophagocytic Antibodies of Intravenous Immunoglobulin Preparations against Seven Streptococcus agalactiae Serotypes

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

초록

Purpose: Group B streptococcus (GBS) is a causative organism of invasive infections in neonates and pregnant women as well as in non-pregnant adults. Among 10 known serotypes of GBS, uncommon serotypes, such as IV and VI to IX, can cause invasive infections in immunocompromised patients. However, opsonophagocytic antibodies against these serotypes in human sera and intravenous immunoglobulin (IVIG) have not yet been studied. IVIG therapy is used to treat or prevent invasive infections in patients with primary antibody deficiencies. Here, we analyzed the activity of opsonophagocytic antibodies against GBS in IVIG preparations. Methods: Opsonophagocytic antibody activity (opsonic index [OI]) against seven GBS serotypes (II and IV to IX) was evaluated in 16 commercially available IVIG preparations using the opsonophagocytic assay (OPA) in HL-60 cells and baby rabbit complement assay during 2015–2016 in South Korea (UAB GBS OPA, at http://www.vaccine.uab.edu). Results: The estimated serum trough levels of OIs against GBS exceeded the limit of detection (≥4) in all IVIG preparations. For serotype VII, the serum levels of OIs were 6–136, the lowest among all serotypes. An IVIG dose of 400 mg/kg was found to be appropriate for immunocompromised individuals to prevent invasive GBS infections. Conclusions: Most immunoglobulin products displayed high levels of opsonophagocytic activity against GBS, except for serotype VII. IVIG preparations could serve as a therapeutic or immunomodulatory agent for immunocompromised individuals.

Abstract

Purpose: Group B streptococcus (GBS) is a causative organism of invasive infections in neonates and pregnant women as well as in non-pregnant adults. Among 10 known serotypes of GBS, uncommon serotypes, such as IV and VI to IX, can cause invasive infections in immunocompromised patients. However, opsonophagocytic antibodies against these serotypes in human sera and intravenous immunoglobulin (IVIG) have not yet been studied. IVIG therapy is used to treat or prevent invasive infections in patients with primary antibody deficiencies. Here, we analyzed the activity of opsonophagocytic antibodies against GBS in IVIG preparations. Methods: Opsonophagocytic antibody activity (opsonic index [OI]) against seven GBS serotypes (II and IV to IX) was evaluated in 16 commercially available IVIG preparations using the opsonophagocytic assay (OPA) in HL-60 cells and baby rabbit complement assay during 2015–2016 in South Korea (UAB GBS OPA, at http://www.vaccine.uab.edu). Results: The estimated serum trough levels of OIs against GBS exceeded the limit of detection (≥4) in all IVIG preparations. For serotype VII, the serum levels of OIs were 6–136, the lowest among all serotypes. An IVIG dose of 400 mg/kg was found to be appropriate for immunocompromised individuals to prevent invasive GBS infections. Conclusions: Most immunoglobulin products displayed high levels of opsonophagocytic activity against GBS, except for serotype VII. IVIG preparations could serve as a therapeutic or immunomodulatory agent for immunocompromised individuals.

참고문헌 (40)

  1. Phares CR, "Epidemiology of invasive group B streptococcal disease in the United States, 1999–2005", JAMA, 299, pp.2056~2065 (2008)
  2. Le Doare K, "An overview of global GBS epidemiology", Vaccine, 31(Suppl 4), pp.D7~D12 (2013)
  3. Baker CJ, "Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection", N Engl J Med, 294, pp.753~756 (1976)
  4. Edwards MS, "Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines", Vaccine, 30, pp.4123~4126 (2012)
  5. Harrison LH, "Emergence of serotype V group B streptococcal infection among infants and adults", J Infect Dis, 171, pp.513~ (1995)
  6. Lin FY, "Capsular polysaccharide types of group B streptococcal isolates from neonates with early-onset systemic infection", J Infect Dis, 177, pp.790~792 (1998)
  7. Ferrieri P, "Serotype IV and invasive group B streptococcus disease in neonates, Minnesota, USA, 2000–2010", Emerg Infect Dis, 19, pp.551~558 (2013)
  8. Melin P, "Group B streptococcal epidemiology and vaccine needs in developed countries", Vaccine, 31(Suppl 4), pp.D31~D42 (2013)
  9. Lamagni TL, "Emerging trends in the epidemiology of invasive group B streptococcal disease in England and Wales, 1991–2010", Clin Infect Dis, 57, pp.682~688 (2013)
  10. Lachenauer CS, "Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women", J Infect Dis, 179, pp.1030~1033 (1999)
  11. 이준호, "Etiology of Invasive Bacterial Infections in Immunocompetent Children in Korea (1996-2005): A Retrospective Multicenter Study", Journal of Korean Medical Science, 26(2), pp.174~183 (2011), 대한의학회
  12. 조혜경, "The Causative Organisms of Bacterial Meningitis in Korean Children in 1996-2005", Journal of Korean Medical Science, 25(6), pp.895~899 (2010), 대한의학회
  13. Yoon IA, "Clinical significance of serotype V among infants with invasive group B streptococcal infections in South Korea", Int J Infect Dis, 38, pp.136~140 (2015)
  14. Fischer GW, "Immunoglobulin therapy for neonatal sepsis : an overview of animal and clinical studies", J Clin Immunol, 10, pp.40S~46S (1990)
  15. Shehata N, "The use of immunoglobulin therapy for patients with primary immune deficiency : an evidence-based practice guideline", Transfus Med Rev, 24(Suppl 1), pp.S28~S50 (2010)
  16. Baker CJ, "Potential use of intravenous immune globulin for group B streptococcal infection", Rev Infect Dis, 12(Suppl 4), pp.S476~S482 (1990)
  17. Baker CJ, "Role of intravenous immunoglobulin in prevention of late-onset infection in low-birth-weight neonates. The Neonatal IVIG Study Group", Rev Infect Dis, 12(Suppl 4), pp.S463~S469 (1990)
  18. 김한울, "Opsonophagocytic Antibodies to Serotype Ia, Ib, and III Group B Streptococcus among Korean Infants and in Intravenous Immunoglobulin Products", Journal of Korean Medical Science, 32(5), pp.737~743 (2017), 대한의학회
  19. Lee S, "Functional antibodies to Haemophilus influenzae type b, Neisseria meningitidis, and Streptococcus pneumoniae contained in intravenous immunoglobulin products", Transfusion, 57, pp.157~165 (2017)
  20. Schuchat A, "Group B streptococcus", Lancet, 353, pp.51~56 (1999)
  21. Kwatra G, "Natural acquired humoral immunity against serotype-specific group B streptococcus rectovaginal colonization acquisition in pregnant women", Clin Microbiol Infect, 21, pp.568.e13~568.e21 (2015)
  22. Francois Watkins LK, "Epidemiology of invasive group B streptococcal infections among nonpregnant adults in the United States, 2008–2016", JAMA Intern Med, 179, pp.479~488 (2019)
  23. Madzivhandila M, "Serotype distribution and invasive potential of group B streptococcus isolates causing disease in infants and colonizing maternal-newborn dyads", PLoS One, 6, pp.e17861~ (2011)
  24. Mikolajczyk MG, "Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations", Clin Diagn Lab Immunol, 11, pp.1158~1164 (2004)
  25. Takahashi Y, "IgG levels against 13-valent pneumococcal conjugate vaccine serotypes in non pneumococcal conjugate vaccine immunized healthy Japanese and intravenous immunoglobulin preparations", J Infect Chemother, 20, pp.794~798 (2014)
  26. Adam E, "Antibody levels to Bordetella pertussis and Neisseria meningitidis in immunodeficient patients receiving immunoglobulin replacement therapy", J Clin Immunol, 35, pp.213~217 (2015)
  27. Imbach P, "High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood", Lancet, 1, pp.1228~1231 (1981)
  28. Garcia-Lloret M, "Immunoglobulin replacement therapy in children", Immunol Allergy Clin North Am, 28, pp.833~849 (2008)
  29. Quinti I, "Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies : results from a multicenter prospective cohort study", J Clin Immunol, 31, pp.315~322 (2011)
  30. Lucas M, "Infection outcomes in patients with common variable immunodeficiency disorders : relationship to immunoglobulin therapy over 22 years", J Allergy Clin Immunol, 125, pp.1354~1360 (2010)
  31. Radosevich M, "Intravenous immunoglobulin G : trends in production methods, quality control and quality assurance", Vox Sang, 98, pp.12~28 (2010)
  32. 어영, "임신부의 Group B Streptococci 보균율, 혈청형 및 Macrolide-Lincosamide-StreptograminB 내성형의 분포", Annals of Clinical Microbiology, 12(4), pp.174~179 (2009), 대한임상미생물학회
  33. 오지은, "임신부에서 분리된 B군 연구균의 중합효소연쇄반응과 염기서열분석을 통한 혈청형 분석", Pediatric Infection and Vaccine, 16(1), pp.47~53 (2009), 대한소아감염학회
  34. Hong JS, "Genital group B streptococcus carrier rate and serotype distribution in Korean pregnant women : implications for group B streptococcal disease in Korean neonates", J Perinat Med, 38, pp.373~377 (2010)
  35. Edwards JM, "Group B streptococcus(GBS)colonization and disease among pregnant women : a historical cohort study", Infect Dis Obstet Gynecol, 2019, pp.5430493~ (2019)
  36. Zhu Y, "Group B streptococcus colonization in late pregnancy and invasive infection in neonates in China : a population-based 3-year study", Neonatology, 115, pp.301~309 (2019)
  37. Norrby-Teglund A, "Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis : a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis", J Intern Med, 260, pp.509~516 (2006)
  38. Romero-Steiner S, "Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines", Clin Vaccine Immunol, 13, pp.165~169 (2006)
  39. Baker CJ, "Maternal antibody at delivery protects neonates from early onset group B streptococcal disease", J Infect Dis, 209, pp.781~788 (2014)
  40. Dangor Z, "Correlates of protection of serotype-specific capsular antibody and invasive group B streptococcus disease in South African infants", Vaccine, 33, pp.6793~6799 (2015)

관련 논문AI추천

Group B Streptococcus Vaccines: Progress and Potential김선주, Kristin Widyasari대한임상미생물학회 · Annals of Clinical Microbiology2023 · 제26권 제3호Association of Immunoglobulin G at Birth with Late-Onset Sepsis and Related Mortality in Very Low Birth Weight Infants김애경, 김지현, 김한석, 신승한, 신재석, 신정민, 윤영미, 윤혜리, 조한나대한신생아학회 · Neonatal medicine2017 · 제24권 제4호Genotypic Distribution of Alpha-Like Proteins in Group B Streptococcus Strains Isolated in Korea: Implications for Vaccine CoverageCho Hye-Kyung, Jo Dae Sun, Kim Han Wool, Kim Kyung-Hyo, Lee Hyunju, Lee Ji Hyen대한감염학회 · Infection and Chemotherapy2025 · 제57권 제2호한국 신생아에서 B군 사슬알균 감염증오지은대한소아감염학회 · Pediatric Infection and Vaccine2012 · 제19권 제2호Comparative Analysis of the Molecular Characteristics of Group B Streptococcus Isolates Collected from Pregnant Korean Women Using Whole-genome Sequencing어영, 이혁민, Bae Hye Gyung, Choi Jong Rak, Lee Kyungwon, Lee Yangsoon, Won Dongju, Yun Woobin대한진단검사의학회 · Annals of Laboratory Medicine2023 · 제43권 제2호Antibody Responses in Hematopoietic Cell Transplantation Recipients after Vaccination Against Haemophilus Influenzae Type b and Streptococcus pneumoniae공은혜, 구홍회, 김경효, 김양현, 김예진, 박기섭, 성기웅, 유건희, 최수한, 황지영대한소아감염학회 · Pediatric Infection and Vaccine2014 · 제21권 제2호

이 간행물의 다른 논문 (5건)